Related references
Note: Only part of the references are listed.Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails
Y. Niu et al.
ONCOGENE (2010)
Possible involvement of androgen receptor alterations in hepatocarcinogenesis
M. Barone et al.
DIGESTIVE AND LIVER DISEASE (2009)
Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-α expression
Jiann-Jyh Lai et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
DR5 receptor mediates anoikis in human colorectal carcinoma cell lines
Luciana M. Laguinge et al.
CANCER RESEARCH (2008)
Involvement of protein kinase C beta-extracellular signal-regulating kinase(1/2)/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion
Kun Guo et al.
CANCER SCIENCE (2008)
Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma
Cheng-Lung Ma et al.
GASTROENTEROLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Androgen receptor is a tumor suppressor and proliferator in prostate cancer
Yuanjie Niu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Is human hepatocellular carcinoma a hormone-responsive tumor?
Massimo Di Maio et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
p38 pathway kinases as anti-inflammatory drug targets
J. F. Schindler et al.
JOURNAL OF DENTAL RESEARCH (2007)
The expression of estrogen receptors in hepatocellular carcinoma in Korean patients
Ai Guo Wang et al.
YONSEI MEDICAL JOURNAL (2006)
Intracellular survival pathways in the liver
Tom Luedde et al.
LIVER INTERNATIONAL (2006)
Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma
R-H Yuan et al.
JOURNAL OF PATHOLOGY (2006)
Direct activation of TGF-β1 transcription by androgen and androgen receptor complex in Huh7 human hepatoma cells and its tumor in nude mice
G Yoon et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Circulating messenger RNA of α-fetoprotein -: A possible risk factor of recurrence after resection of hepatocellular carcinoma
KS Jeng et al.
ARCHIVES OF SURGERY (2004)
Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature
LX Qin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Androgjen receptor expression is inversely correlated with pathologic, tumor stage in bladder cancer
S Boorjian et al.
UROLOGY (2004)
Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen
JC Trinchet et al.
HEPATOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Generation and characterization of androgen receptor knockout (ARKO) mice:: An in vivo model for the study of androgen functions in selective tissues
SY Yeh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)